Lilly posts Phase 3 orforglipron results; registers new MDD trial and five other updates
A week of registry activity spans posted Phase 3 diabetes results, a new antidepressant trial, and five other Lilly-linked studies in various phases.
Eli Lilly and Company registry records showed seven updates this week, led by the first posting of Phase 3 results for its oral GLP-1 drug.
- The Phase 3 "ACHIEVE-5" study of orforglipron in adults with Type 2 diabetes on insulin glargine is completed with results first posted. The study compared once daily oral orforglipron with placebo in adult participants with Type 2 diabetes and inadequate glycemic control on insulin glargine, with or without metformin and/or an SGLT-2 inhibitor.1 Enrollment was 546 participants, with the primary outcome measuring change from baseline in HbA1c at Week 40.1
- A new Phase 3 study of brenipatide, called "RENEW-MDD- 2," is recruiting for major depressive disorder. The trial evaluates brenipatide added to standard of care against placebo plus standard of care in delaying the return of major depressive symptoms.2 Estimated enrollment is 1000 participants, with the primary outcome tracking time to relapse.2 The study spans 169 sites in 15 countries including the United States, Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan and the United Kingdom.2
- A Phase 2 study of LY3841136 alone or combined with tirzepatide in adults with obesity or overweight and Type 2 diabetes is completed. The study, run under master protocol W8M-MC-CWMM, examined safety and efficacy of LY3841136 for chronic weight management, alone or with tirzepatide, across a range of doses in participants with Type 2 diabetes.3 Enrollment was 367 participants, with the primary outcome measuring percent change from baseline in body weight at Week 48.3
- A Phase 1 study of eloralintide (LY3841136) in healthy participants is active but not recruiting. The study evaluates safety, tolerability and pharmacokinetics of two different eloralintide solutions.4 Estimated enrollment is 58 participants, comparing a reference and a test formulation administered subcutaneously.4
- A new Phase 1 study of LY4560736 in healthy participants and those with Alzheimer's Disease is not yet recruiting. The study examines the drug's safety and how much and how quickly it reaches the bloodstream, and in healthy participants also measures how much reaches the brain.5 Estimated enrollment is 111 participants.5
- A Phase 2 study of baricitinib (Olumiant) in adults of African descent with central centrifugal cicatricial alopecia, sponsored by Raven Clinical Research with Eli Lilly as collaborator, is completed. The study evaluated safety and efficacy of baricitinib 4 mg daily in a scarring alopecia for which no FDA-approved treatment exists.6 Twenty-seven participants received at least one dose and 17 completed the Day 365 visit.6
- A Phase 4 safety study of insulin lispro-aabc (Lyumjev) in Type 2 diabetes patients in India, sponsored by Eli Lilly with Cipla Ltd. as collaborator, is completed with results posted. The study assessed the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.7 Enrollment was 153 participants, who received insulin lispro-aabc before meals alongside once-daily insulin glargine over a 26-week treatment period.7
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.